Blog

Harout Semerjian: It was an honor to be appointed to the Biotechnology Innovation Organization’s Board of Directors, Emerging Companies Section

Photo taken from Harout Semerjian/LinkedIn

Oct 31, 2023, 10:23

Harout Semerjian: It was an honor to be appointed to the Biotechnology Innovation Organization’s Board of Directors, Emerging Companies Section

Harout Semerjian, President and CEO at GlycoMimetics, posted on LinkedIn:

“It was an honor this week to be appointed to the Biotechnology Innovation Organization’s (BIO) Board of Directors, Emerging Companies Section. Our sector has the opportunity and responsibility to engage stakeholders as we advance innovation to improve the lives of patients. Dialogue is critical to overcoming the challenges we face in delivering on the promise of our unique mission.

A special shoutout to the incredible CEOs who welcomed me and shared their inspiring stories. Thankfully, we have leaders with resilience and grit, who advance their programs in challenging capital markets with grace and a smile!”

Source: Harout Semerjian/LinkedIn

Biotechnology Biotechnology Innovation Organization cancer Elizabeth Jeffords Erika Smith GlycoMimetics Grace Colón Harout Semerjian Julia Owens OncoDaily Oncology Rachel King Sulagna Bhattacharya Ted Love

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology